CRNX
Crinetics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRNX
Crinetics Pharmaceuticals, Inc.
A clinical stage pharmaceutical company focused on novel therapeutics for rare endocrine diseases and endocrine-related tumors
6055 Lusk Boulevard, San Diego, California 92121
--
Crinetics Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on November 18, 2008. The company is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of new drugs for the treatment of rare endocrine diseases and endocrine-related tumors. The function of the endocrine pathway is to maintain homeostasis, and peptide hormones acting through G protein-coupled receptors or GPCRs are commonly used to regulate many aspects of physiology, including growth, energy, metabolism, gastrointestinal function and stress response.
Earnings Call
Q3/2025
Estimate EPS-1.25
Actual EPS-1.38
Estimate Revenue394.00K
Actual Revenue143.00K
Crinetics' Q3 2025: Contradictions Emerge on Patient Enrollment, Launch Strategy, Reimbursement, and Prescriber Engagement
Nov 09,2025 03:22
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CRNX has released its 2025 Q3 earnings. EPS was reported at -1.38, versus the expected -1.25, missing expectations. The chart below visualizes how CRNX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRNX has released its 2025 Q3 earnings report, with revenue of 143.00K, reflecting a YoY change of NaN%, and net profit of -130.09M, showing a YoY change of -69.33%. The Sankey diagram below clearly presents CRNX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
